Online Trial Tracker - Larvol Sigma

Welcome, Profile Billing Logout

1 Trials

All TrialsPhase 2

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

PF582 (ranibizumab biosimilar) / Ligand

NCT02121353: Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration

	Initial results of PF582 compared to Lucentis
	Sep 2016 - Sep 2016: Initial results of PF582 compared to Lucentis

Completed

1/2

RoW

Lucentis, ranibizumab, PF582

Pfenex, Inc

Age Related Macular Degeneration (AMD)

01/16

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites